Breast cancer is the most frequently diagnosed cancer in women,which poses a great threat to women's health.Human epidermal growth factor receptor 2(HER-2)is an important target for the treatment of breast cancer,and targeted therapy for HER-2-positive breast cancer has been widely studied.HER-2 low expression was previously classified as negative breast cancer and rarely or could not benefit from traditional anti-HER-2 therapy.However,with the established efficacy of antibody-drug conjugates,HER-2-low expressing breast cancer has become a new subtype for treatment.This article will summarize the definition,clinicopathological features,prognosis and treatment progress of HER-2-low expressing breast cancer.
维普
万方数据